Navigating Medical Device Reimbursement in Germany: What Manufacturers Need to Know
Germany is one of Europe’s largest healthcare markets, but successfully bringing a medical device to German patients requires more than MDR certification. To be competitive, manufacturers must also consider reimbursement pathways early in their market strategy....
Building a Strong Clinical Evaluation: CEP, CER, and the Power of Literature
In the world of medical devices under EU MDR (EU 2017/745), the clinical evaluation process is a cornerstone of demonstrating safety and performance. At its heart are two interlinked documents: the Clinical Evaluation Plan (CEP) - which defines how you’ll gather...
Ensuring Biological Safety with BEP & BER Under MDR — What You Need to Know Now
Biological safety remains a critical part of bringing a medical device to market under EU MDR (EU 2017/745). Two documents in particular matter: the Biological Evaluation Plan (BEP), which lays the groundwork for identifying and managing biological risks; and the...
Leveraging FDA Approval for Global Growth: Strategic Considerations for Medical Device Manufacturers
For many medical device companies, the United States is not only one of the largest healthcare markets in the world—it’s also a gateway to global opportunities. FDA clearance or approval is widely recognized as a gold standard in medical device regulation, and...
Navigating Regulatory Pathways: FDA vs. EU-MDR Explained
When bringing a medical device to market, one of the most important strategic choices manufacturers face is deciding whether to pursue approval in the United States under the FDA or in the European Union under the EU-MDR. Both frameworks are globally respected, but...
From First Patient to Final Report: How CRO Expertise Ensures Quality and Compliance
Once your clinical investigation is underway, the focus shifts from planning and preparation to execution, oversight, and data integrity. This stage is where the evidence needed for MDR (EU 2017/745) compliance—and ultimately market approval—is gathered, validated,...
From Planning to First Patient: How Early-Phase CRO Support Sets Your Clinical Investigation Up for Success
While the past weeks have been quieter on our blog, our work behind the scenes has been as active as ever—supporting medical device companies in planning, managing, and executing clinical investigations. Now that the vacation season is winding down, we’re kicking...
Taming Documentation Chaos: Practical MDR Compliance Tips
Throughout this spring, we’ve seen firsthand how medical device companies navigate the complex landscape of MDR—not only during audits but in the day-to-day realities of quality system maintenance. One insight has become increasingly clear: even well-established...
Lessons from MDR Audits: How Strong Collaboration and Clinical Ownership Drive Success
This spring, our consultants at MDS have been deeply involved in several intensive regulatory milestones. We supported clients through multiple Stage 1 and Stage 2 MDR audits, and participated in the TDA (Technical Documentation Assessment) process for various...
Navigating the Transition from IVDD to IVDR: Key Changes and Deadlines
The shift from the In Vitro Diagnostic Directive (IVDD) to the In Vitro Diagnostic Regulation (IVDR) represents a significant overhaul in the regulatory landscape for in vitro diagnostic medical devices within the European Union. This transition aims to enhance...
